Determination of cilostazol and its active metabolite 3,4-dehydro cilostazol from small plasma volume by UPLC−MS/MS

US Department of Health and Human Services, Food and Drug Administration. NME Drug and New Biological Approval in 1999. Available from: 〈http://www.fda.gov/…/howdrugsaredevelopedandapproved/drugandbiologicapprovalreports/ucm081686.htm〉 (Last accessed April, 2014).

Al-Qudah, 2011, Cilostazol in patients with ischemic stroke, Expert. Opin. Pharmacother., 12, 1305, 10.1517/14656566.2011.576248

Liu, 2011, Phosphodi Esterases as Drug Targets, 211, 10.1007/978-3-642-17969-3_9

Liu, 2001, Cilostazol (Pletal®): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake, Cardiovasc. Drug Rev., 19, 369, 10.1111/j.1527-3466.2001.tb00076.x

Hiratsuka, 2007, Characterization of human cytochrome P450 enzymes involved in the metabolism of cilostazol, Drug Metab. Dispos., 35, 1730, 10.1124/dmd.107.016758

Akiyama, 1985, High-performance liquid chromatographic procedure for the determination of a new antithrombotic and vasodilating agent, cilostazol, in human plasma, J. Chromatogr., 338, 456, 10.1016/0378-4347(85)80121-3

Bramer, 2001, Method for the quantitative analysis of cilostazol and its metabolites in human plasma using LC/MS/MS, J. Pharm. Biomed. Anal., 26, 637, 10.1016/S0731-7085(01)00436-8

Nirogi, 2006, Simultaneous quantification of cilostazol and its primary metabolite 3,4-dehydrocilostazol in human plasma by rapid liquid chromatography/tandem mass spectrometry, Anal. Bioanal. Chem., 384, 780, 10.1007/s00216-005-0198-z

Tata, 2001, Determination of cilostazol and its metabolites in human urine by high performance liquid chromatography, J. Pharm. Biomed. Anal., 24, 381, 10.1016/S0731-7085(00)00426-X

Yeon, 2005, High performance liquid chromatographic analysis of cilostazol, in human plasma with on-line column switching, J. Liq. Chromatogr. Relat. Technol., 28, 109, 10.1081/JLC-200038606

FDA, Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), and Centre for Veterinary Medicine (CVM), 2001.

FDA, Guidance for Industry: ICH E6 Good Clinical Practice. US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), Centre for Biologics Evaluation and Research (CBER), 1996.

Chesnut, 2007, The role of UHPLC in pharmaceutical development, J. Sep. Sci., 30, 1183, 10.1002/jssc.200600505

Woo, 2002, Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans, Clin. Pharmacol. Ther., 71, 246, 10.1067/mcp.2002.122474

Yadav, 2011, Incurred sample reanalysis (ISR): a decisive tool in bioanalytical research, Bioanalysis, 3, 1007, 10.4155/bio.11.76